Lancet Infectious Diseases

Papers
(The H4-Index of Lancet Infectious Diseases is 96. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Adaora “Ada” Alise Adimora1502
A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis1151
Highlights from the sixth ESCMID Conference on Vaccines1012
DNDi receives Dutch funding boost556
HIV vaccine trial failure539
Research in brief417
Malaria outbreak in Laos caused by formerly rare artemisinin resistant strains of Plasmodium falciparum413
Research in brief411
COVID-19 vaccination protects children and adolescents364
A patient with secondary syphilis following incomplete treatment of primary infection361
Environment and infectious diseases340
Promoting diversity and equity in publishing304
Efficacies of artemether–lumefantrine, artesunate–amodiaquine, dihydroartemisinin–piperaquine, and artesunate–pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children 287
A step forward in the journey towards hookworm vaccines282
Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial276
Correction to Lancet Infect Dis 2024; published online April 3. https://doi.org/10.1016/S1473-3099(24)00142-7264
Chikungunya vaccine VLA1553 induces sustained protective antibody concentrations252
Listeria monocytogenes: a rare, deadly cause of peritonitis252
GoGoVax dispels hopes for gonorrhoea vaccination248
Updated criteria for paediatric sepsis and septic shock243
Correction to Lancet Infect Dis 2025; 25: e280–93237
Infectious disease surveillance update230
Evaluating improved inactivated oral cholera vaccines for use in ending endemic cholera by 2030: opportunities and challenges229
Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation222
Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study222
Host cell entry and neutralisation sensitivity of the emerging SARS-CoV-2 variant LP.8.1219
The superiority of bivalent over monovalent booster vaccines214
The lasting lessons of mpox: infection, vaccination, and immune memory209
Below-knee amputation following osteomyelitis from multidrug-resistant Stenotrophomonas maltophilia in a diabetic foot ulcer209
Attention to skin-related neglected tropical diseases209
Shaping opportunities for future clinical trials in tuberculosis205
Ivan Hirsch200
Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden189
Relaxation of anti-COVID-19 measures reveals new challenges for infectious disease outbreak forecasting182
Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the C181
The next chapter for Africa's genomic initiatives175
Human papillomavirus (HPV) type 16 and type 18 antibody concentrations after a single dose of bivalent HPV vaccine in girls aged 9–14 years compared with three doses of quadrivalent HPV vaccine in wom172
Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic172
Circulation of avian Chlamydia abortus in the Netherlands and community-acquired pneumonia: an outbreak investigation and retrospective cohort study165
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b tria164
Selection of Neisseria gonorrhoeae ceftriaxone resistance using doxycycline post-exposure prophylaxis164
Measles immunity gaps and outbreak risk in a shifting landscape163
Best practice guidelines for viral hepatitis service delivery in prisons154
Mpox in people with past infection or a complete vaccination course: a global case series154
Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial151
Kyasanur Forest disease: an emerging arboviral threat149
Oral treatment of Whipple's disease with doxycycline and hydroxychloroquine versus intravenous therapy with ceftriaxone followed by oral trimethoprim–sulfamethoxazole in Germany: a phase 2/3, prospect146
Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations145
Neuropathology, pathomechanism, and transmission in zoonotic Borna disease virus 1 infection: a systematic review144
Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-inco144
Surge of cutaneous leishmaniasis in Pakistan143
Threat of HIV and tuberculosis drug resistance after US funding cuts141
Reflecting on lessons from the 2014–16 Ebola virus outbreak141
Effectiveness of ceftazidime–avibactam versus ceftolozane–tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study141
Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trial140
Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial139
Research in brief139
Research in brief138
New flavours of tuberculosis treatment for children137
A new monoclonal in the arMAMentarium against malaria137
Twin threats: climate change and zoonoses136
Are we underestimating the annual risk of infection with Mycobacterium tuberculosis in high-burden settings?136
We need estimates of gonorrhoea vaccine protection and symptomaticity by sex and anatomical site135
BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents135
Global cholera resurgence—a preventable tragedy135
WHO's first global infection prevention and control report134
An observer-blind, randomised, placebo-controlled, phase 1, single ascending dose study of dengue monoclonal antibody in healthy adults in Australia133
Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022–23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance study132
When mpox is not mpox: varicella and measles in DR Congo132
Is combination antiviral therapy for influenza the optimal approach?130
Addressing the shortage of cholera vaccines127
The implications of mpox breakthrough infections on future vaccination strategies122
Theresa Ochoa—staying on top of infectious diseases in Peru121
Research in brief118
RSV prevention: public health lessons from the southern hemisphere117
Full-dose NSAIDs at the first sign of respiratory infection?115
Severe influenza: is there a role for antiviral combinations?113
Election of Regional Director for the Western Pacific113
Tuberculosis recovery in Georgia: implementing more by 24113
Emil Gotschlich113
Supporting healthcare access for refugees and migrants111
Interplay of infection and vaccination in long-term protection from COVID-19110
Effectiveness of SARS-CoV-2 vaccines in the post-natural infection world110
Serpiginous-like choroiditis in ocular tuberculosis109
Pre-emptively tackling vaccine misinformation for a successful large-scale roll-out of malaria vaccines in Africa104
COVID-19 mortality in Africa and Asia – Authors' reply104
Infectious disease surveillance update104
High-dose primaquine reduces vivax relapses: time for change103
Elisabeth Presterl—always looking forward103
Research in brief102
Immune evasiveness of SARS-CoV-2 variants and vaccine selection100
The response of mpox-associated inflammatory syndrome to steroid therapy100
Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis98
Correction to Lancet Infect Dis 2022; published online Aug 31. https://doi.org/10.1016/S1473-3099(22)00434-097
Correction to Lancet Infect Dis 2023; published online Dec 15. https://doi.org/10.1016/S1473-3099(23)00744-297
Correction to Lancet Infect Dis 2023; 23: e46997
Correction to Lancet Infect Dis 2024; published online Feb 1. https://doi.org/10.1016/S1473-3099(23)00706-596
0.52238297462463